NCT04850495View on ClinicalTrials.gov

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions

Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaTransformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

DRUG

Zanubrutinib

Given PO

Trial Locations (3)

29425

RECRUITING

MUSC, Charleston

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

44195

RECRUITING

Cleveland Clinic, Cleveland

All Listed Sponsors

lead

Yazeed Sawalha

OTHER

NCT04850495 - Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter